U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038304) titled 'The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)' on March 04.
Brief Summary: In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones. This will lead to the stage of metastatic castration-refractory prostate can-cer (mCRPC), which is incurable and results in a median overall survival of 2-3 years.
Treatment options for patients with mCRPC include several systemic agents, such as andro-gen receptor-targeted agents (A...